Prestige BioPharma (PBP) is a Singapore based biopharmaceutical company focusing on development of biosimilars and new antibody therapeutics. PBP has strong presence and networks in Asia Pacific region and actively penetrating into the global pharmaceutical market. The successful completion of phase I clinical trial on its first biosimilar HD201 (Trastuzumab) in EU, 2014, has placed PBP amongst the top-tier biosimilar developers.
The primary focus of current PBP’s R&D is oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis. In parallel with our efforts to enhance safety, efficacy, and affordability of existing antibody therapeutics, PBP thrive to search for new targets and candidates to address the unmet medical needs in oncology, immunology, and degenerative & metabolic disorders.
The Prestige Group originating from a Singapore government invested research institution comprises Prestige BioPharma Singapore, Prestige BioResearch Singapore and PrestigeBio Pharmaceuticals GMP manufacturing facilities in Korea. With its solid financial and operational stability, Prestige support and expedite future biologics development and commercialization in a concerted approach and together become one of the most competitive players in the global biopharmaceutical industry. Prestige Biologics Co. Ltd., Korea is Prestige BioPharma’s dedicated GMP manufacturer and global business partner. For more information, please visit here.